Vaxcyte, Inc (PCVX) Reports Positive Data from Phase 2 Study

Vaxcyte, Inc (PCVX) Reports Positive Data from Phase 2 Study of VAX-24

Vaxcyte, Inc (PCVX) Reports Positive Data from Phase 2 Study of VAX-24
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Janet Graesser , Jim Wassil , Jennifer Zibuda , Groupa Strep , Drug Administration , Adult Clinical Program , Vaxcyte Inc , Adult Program , Exchange Commission , Nasdaq , Company To Host Webcast Conference Call , Sutro Biopharma Inc , Investor Relationsvaxcyte Inc , Investor Relations Vaxcyte Inc , Corporate Communications , Robust Immune Responses Across , All Doses , Confirming Prior Phase , Adults Aged , Dose Met Opsonophagocytic Activity , Response Non Inferiority Criteria , Superiority Criteria , Four Additional , Dose Showed Further Improvement , Overall Immune Responses , Six Month Safety Data , Both Adult Studies Demonstrated , Tolerability Results Similar , Pooled Immunogenicity Analyses , Both Adult Phase , Dose Met , Inferiority Criteria , Adult Phase , Topline Data Anticipated , Conference Call Today , Grant Pickering , Chief Executive Officer , Executive Vice President , Chief Operating Officer , Both Adult Studies The Company , Principal Investigator , Key Milestonesvaxcyte , Investigational New Drug , Proof Of Concept Study , Breakthrough Therapy , Pneumococcal Diseasepneumococcal , Sutro Biopharma , Looking Statementsthis , Private Securities Litigation Reform Act , Annual Report , Vice President , Investor Relationsvaxcyte , Senior Director , Investor Relations Vaxcyte ,